SLC6A11

Across TCGA pan-cancer cohorts, SLC6A11 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SLC6A11’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SLC6A11 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC6A11 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.

LUAD, HNSC, and LIHC are the cancer types where SLC6A11 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC6A11 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	+0.955	<.001	9	view →
HNSC	Female	IV	+2.661	<.001	6	view →
LIHC	Female	All	+1.767	<.001	6	view →
LUSC	Male	All	+1.167	<.001	5	view →
COAD	Female	II,III,IV	−0.037	<.001	5	view →
READ	All	All	−0.033	.021	3	view →
PRAD	All	All	+0.972	<.001	2	view →
UCEC	All	All	−0.400	.031	2	view →
CHOL	All	All	+1.326	.023	1	view →
KIRC	Male	All	+0.009	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SLC6A11–LUAD

Open the LUAD breakdown →